Trial · NCT07135973
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
NCT07135973, Phase 4, Not yet recruiting, Sanofi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD). Trials, record NCT07135973. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07135973
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
- NCT number
- NCT07135973
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 26 participants, estimated
- Lead sponsor
- Sanofi
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil
- First posted
- 2025-08-22
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) | From baseline to 24 weeks | Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) during the treatment period (24 weeks) |
| Secondary | Best overall Response (BoR) | Baseline to end of study i.e. 12 months | Best overall Response (BoR), defined as the proportion of patients who achieved complete response (CR) or partial response (PR) according to the NIH Consensus Criteria. |
| Secondary | Duration of Response (DOR) | Baseline to end of study i.e. 12 months | Duration of Response (DOR) calculated from time of initial PR or CR until documented progression, death, or new systemic therapy. |
| Secondary | Time to Response (TTR) | Baseline to end of study i.e. 12 months | |
| Secondary | Response by organ system (including GSR) | Baseline to end of study i.e. 12 months | |
| Secondary | Time taken for New Treatment (TTNT) or death | Baseline to end of study i.e. 12 months | |
| Secondary | Failure-free survival (FFS) | Baseline to end of study i.e. 12 months | |
| Secondary | Overall survival (OS) | Baseline to end of study i.e. 12 months | |
| Secondary | Change in Corticosteroid dose. | Baseline to end of study i.e. 12 months | |
| Secondary | Change in CNI dose | Baseline to end of study i.e. 12 months |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07135973
GET https://conductscience.org/api/trials/v1/NCT07135973/registered